What is Unity Biotechnology, Inc.'s current stock price?

Unity Biotechnology, Inc. (UBX) currently trades at USD 0.2001. Track real-time price changes and historical performance on AllInvestView.

What sector is Unity Biotechnology, Inc. in?

Unity Biotechnology, Inc. operates in the Health Care sector. AllInvestView lets you analyze sector allocation across your entire portfolio.

Unity Biotechnology, Inc. UBX · Stock Open Unity Biotechnology, Inc. in new tab

0.2001 USD

Add to portfolio

EPS

-1.63

P/B

1.14

ROE

-231.27

Beta

0.93

Target Price

3.00 USD

1M 6M YTD 1Y 2Y 5Y Max

Loading chart...

DCF Valuation

Tweak assumptions to recompute fair value for Unity Biotechnology, Inc. (UBX)

Currency: USD

DCF Assumptions

Revenue growth (YoY) 0.10 Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).

EBITDA margin 0.30 Decimal (e.g., 0.30 = 30%).

Capex (% Revenue) 0.04 Decimal (e.g., 0.04 = 4%).

Tax rate 0.20 Decimal (e.g., 0.20 = 20%).

Terminal growth (g, %) 3% Percent number (e.g., 3 = 3%).

Cost of Equity (%) 10% Percent number (e.g., 10 = 10%).

Cost of Debt (%) 5% Percent number (e.g., 5 = 5%).

DCF Result

Fair Value (DCF)

—

Current Price

—

Upside

—

WACC

—

Terminal PV

—

Σ PV of FCFs

—

Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Unity Biotechnology, Inc. Analysis (UBX)

United States Health Care Official Website Stock

Is Unity Biotechnology, Inc. a good investment? Unity Biotechnology, Inc. (UBX) is currently trading at 0.2001 USD. Market analysts have a consensus price target of 3.00 USD. This suggests a potential upside from current levels.

Investor FAQ

Does Unity Biotechnology, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Unity Biotechnology, Inc.?

Unity Biotechnology, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

Company Profile

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Its lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. The company also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, an a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

Exchange Ticker

NMS (United States) UBX

FRA (Germany) 9U9.F

Trades

Dividend History paid per year (USD)

No dividend history available.

Stock Splits

Split Date	Split Ratio to 1
Oct. 20, 2022	1:10

Unity Biotechnology, Inc. UBX · Stock Open Unity Biotechnology, Inc. in new tab

Key Metrics

Estimates

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features

Unity Biotechnology, Inc. Analysis (UBX)

Investor FAQ

Company Profile

Fundamentals

Under Construction

Unity Biotechnology, Inc. UBX · Stock Open Unity Biotechnology, Inc. in new tab

Key Metrics

Estimates

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features

Unity Biotechnology, Inc. Analysis (UBX)

Investor FAQ

Company Profile

Explore Premium Features

Fundamentals

Under Construction

Community Discussion

Notifications